GlaxoSmithKline (GSK) was downgraded to a Hold Rating at Jefferies
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
pharmaphorum6d
GSK under pressure to rein in new CEO pay
GlaxoSmithKline is under pressure from shareholders to rein in pay for its incoming chief executive, Emma Walmsley, according to reports. Walmsley is set to take over from Sir Andrew Witty when he ...
GlaxoSmithKline Pharmaceuticals Q2 net profit rises 16% to Rs 252 crore
Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, ...
U.S. News & World Report29d
GSK Sues Moderna for US Patent Infringement Over COVID, RSV Vaccines
(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster ...
JD Supra20d
GlaxoSmithKline and Northwestern Sue Moderna for Patent Infringement in Trio of Lawsuits
On October 15, 2024, GSK filed two complaints against Moderna in the District Court for the District of Delaware, asserting that Moderna willfully infringes GSK’s mRNA patent portfolio. In Civil ...
GlaxoSmithKline Consolidated September 2024 Net Sales at Rs 1,010.77 crore, up 5.62% Y-o-Y
Other Operating Income------Total Income From Operations: 1,010.77: 814.65: 956.99: EXPENDITURE ...
devdiscourse15d
GlaxoSmithKline's Strong Quarterly Profit Growth and Special Dividend Declaration
GlaxoSmithKline Pharmaceuticals reported a notable 16% rise in consolidated net profit for the September quarter, reaching Rs 252 crore. This growth was driven by robust sales and brand performance.
GlaxoSmithKline Pharma Q2 results: Net profit rises 16% to Rs 252 cr
GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs 252 crore in the September quarter, aided by robust sales across segments.
India's GlaxoSmithKline Pharma posts higher Q2 profit on strong demand
India's GlaxoSmithKline Pharmaceuticals reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and vaccines.
Investing1d
GlaxoSmithKline Pakistan Ltd (GLAX)
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
money.rediff15d
GlaxoSmithKline Q2 Profit Rises 16% to Rs 252 cr
GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.
Pharmaceutical Technology3h
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...